Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data.

Florent Chevillard

dblp:151/2856 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
0since 2021 · last 2015
0000-0003-1460-1053ORCID · reported

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 67% Computational science and engineering · 33%

Topics — the 3 heaviest of 3, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery
drug metabolism prediction
0.212015
Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6 · Bioinform. 2015
Computational science and engineering › computational chemistry › molecular simulation
molecular dynamics
0.212015
Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6 · Bioinform. 2015
Bioinformatics and computational biology › drug discovery › drug design
structure-based drug design
0.212015
Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6 · Bioinform. 2015

Methods — techniques the papers use, named apart from their topics

support vector machine · 0.2random forest · 0.2naive bayes · 0.2molecular dynamics simulation · 0.2molecular docking · 0.2
YearPublicationVenuePosition
2015 Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6
abstract
MOTIVATION: Cytochrome P450 (CYP) is a superfamily of enzymes responsible for the metabolism of drugs, xenobiotics and endogenous compounds. CYP2D6 metabolizes about 30% of drugs and predicting potential CYP2D6 inhibition is important in early-stage drug discovery. RESULTS: We developed an original in silico approach for the prediction of CYP2D6 inhibition combining the knowledge of the protein structure and its dynamic behavior in response to the binding of various ligands and machine learning modeling. This approach includes structural information for CYP2D6 based on the available crystal structures and molecular dynamic simulations (MD) that we performed to take into account conformational changes of the binding site. We performed modeling using three learning algorithms--support vector machine, RandomForest and NaiveBayesian--and we constructed combined models based on topological information of known CYP2D6 inhibitors and predicted binding energies computed by docking on both X-ray and MD protein conformations. In addition, we identified three MD-derived structures that are capable all together to better discriminate inhibitors and non-inhibitors compared with individual CYP2D6 conformations, thus ensuring complementary ligand profiles. Inhibition models based on classical molecular descriptors and predicted binding energies were able to predict CYP2D6 inhibition with an accuracy of 78% on the training set and 75% on the external validation set.
Virginie Y. Martiny, Pablo Carbonell, Florent Chevillard, Gautier Moroy, Arnaud B. Nicot, Philippe Vayer, Bruno O. Villoutreix, Maria A. Miteva
Bioinform.3